2025年7月16日,强生公司(NYSE: JNJ)公布2025年第二季度财报,核心财务指标超出市场预期,并同步上调全年业绩指引。公司确认,其在软组织手术机器人领域的关键项目Ottava计划于2026财年提交FDA de novo 510(k)审批,标志其在高增长外科平台上的关键推进。得益于医疗科技板块的持续增长,尤其是心血管与伤口闭合产品的拉动,强生股价在财报发布后上涨超过6%,达到每股...
Source Link2025年7月16日,强生公司(NYSE: JNJ)公布2025年第二季度财报,核心财务指标超出市场预期,并同步上调全年业绩指引。公司确认,其在软组织手术机器人领域的关键项目Ottava计划于2026财年提交FDA de novo 510(k)审批,标志其在高增长外科平台上的关键推进。得益于医疗科技板块的持续增长,尤其是心血管与伤口闭合产品的拉动,强生股价在财报发布后上涨超过6%,达到每股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.